A Phase 3 interventional study of Pegylated-interferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-30.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 71st largest by enrollment, is one of 4 that started in 2009, is one of 19 in phase 3, and was the 47th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 53rd largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2009, is one of 9 in phase 3, and was the 25th registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche partner protocol where access to treatment or re-treatment was promised or deemed appropriate following completion of the original protocol ('donor' protocol). Patients who qualify for treatment or re-treatment will begin PEGASYS monotherapy, at a maximum dose of 180 µg weekly, or combination therapy with Copegus, 800-1200 mg daily, as continuation of treatment after the wash-out period defined in their donor protocol. PEGASYS treatment is not to exceed the approved treatment duration of 48 weeks in genotype G1 with a treatment-free follow up period of 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing \< 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
Drug: Pegylated-interferon alfa-2a · Drug: Ribavirin
Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
Also known as: PEG-IFN alfa-2a, Pegasys
Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
Also known as: Copegus, Ro 20-9963
Percentage of Participants Who Experienced at Least 1 Adverse Event.
An adverse event is any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline through 24 weeks after the end of treatment (up to 72 weeks)
| Milestone | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Started | 30 |
| Completed | 16 |
| Not completed | 14 |
| Withdrew: Administrative/other | 2 |
| Withdrew: Insufficient therapeutic response | 2 |
| Withdrew: Violation of selection criteria at entry | 7 |
| Withdrew: Withdrew consent | 3 |
An adverse event is any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage of participants | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Percentage of Participants Who Experienced at Least 1 Adverse Event. | 80.0 |
Collected over Adverse events from the beginning of treatment up to 24 weeks after the end of treatment were reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated-interferon Alfa-2a Plus Ribavirin | — | 4/30 (13.3%) | 23/30 (76.7%) |
| Event | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Retinal haemorrhageEye disorders | 1/30 |
| Conjunctivitis viralInfections and infestations | 1/30 |
| LaryngitisInfections and infestations | 1/30 |
| SinusitisInfections and infestations | 1/30 |
| Arthropod biteInjury, poisoning and procedural complications | 1/30 |
| Rib fractureInjury, poisoning and procedural complications | 1/30 |
| Prothrombin time prolongedInvestigations | 1/30 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/30 |
| Event | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| FatigueGeneral disorders | 16/30 |
| PruritusSkin and subcutaneous tissue disorders | 9/30 |
| NauseaGastrointestinal disorders | 8/30 |
| ChillsGeneral disorders | 7/30 |
| HeadacheNervous system disorders | 7/30 |
| InsomniaPsychiatric disorders | 7/30 |
| RashSkin and subcutaneous tissue disorders | 6/30 |
| AstheniaGeneral disorders | 5/30 |
| Influenza like illnessGeneral disorders | 5/30 |
| DepressionPsychiatric disorders | 5/30 |
| Age Continuous(years) | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Mean | 48.5 ± 9.35 |
| Sex: Female, Male(Participants) | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Female | 18 |
| Male | 12 |
| Race/Ethnicity, Customized(participants) | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Black | 2 |
| Caucasian | 28 |
| Height(cm) | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Mean | 170.0 ± 7.28 |
| Weight(kg) | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Mean | 76.97 ± 16.146 |
| Body Mass Index (BMI)(kg/m^2) | Pegylated-interferon Alfa-2a Plus Ribavirin |
|---|---|
| Mean | 26.5 ± 4.53 |
The record gives a start of Apr 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin